![](images/graphics/blank.gif)
Myelosuppressive chemotherapy
-
Nivestim™ (filgrastim) is a follow-on biologic agent licensed in the EU for the treatment of neutropenia and febrile neutropenia induced by myelosuppressive chemotherapy. Nivestim™ has been studied in phase 2 and 3 clinical trials where its efficacy and safety was found to be similar to its reference product, Neupogen® . Follow-on biologics continue to be scrutinised for safety.
9p
vijennie2711
29-09-2020
8
0
Download
-
Anthracycline adjuvant therapy has taken a particular role in the treatment of early stage breast cancer with an associated decrease in rates of both relapse and death. Their success however has been limited by their myelosuppression and their well-established risk of cardiac dysfunction.
5p
vialabama2711
21-09-2020
11
1
Download
-
Gemcitabine is currently the standard chemotherapy for the adjuvant treatment of pancreatic cancer. This chemotherapeutic agent is generally well-tolerated, myelosuppression and gastrointestinal toxicity being common side effects. Nevertheless, gemcitabine-induced pulmonary toxicity has been rarely reported.
5p
vimale2711
25-08-2020
9
1
Download
-
Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for patients receiving chemotherapy with FN risk of ≥20% or 10% to 20% with defined risk factors.
8p
vimanila2711
25-06-2020
4
1
Download
-
Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.
8p
viputrajaya2711
22-06-2020
9
1
Download
-
Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)—such as pegfilgrastim—for most patients receiving chemotherapy with an intermediate to high risk for FN.
11p
vikuala271
13-06-2020
11
0
Download
-
Posttransplantation Treatment BCR/ABL transcript levels have served as early predictors for hematologic relapse following transplantation. These should facilitate risk-adapted approaches with immunosuppression or TK inhibitor(s), or a combination of the two. Donor leukocyte infusions (without any preparative chemotherapy or GVHD prophylaxis) can induce hematologic and cytogenetic remissions in patients with CML who have relapsed after allogeneic SCT.
6p
thanhongan
07-12-2010
63
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)